Subscribe To
OPK / OPKO Health (OPK) Ties Up for Oral Peptide Tablet Formulations
![OPKO Health (OPK) Ties Up for Oral Peptide Tablet Formulations](https://cdn.snapi.dev/images/v1/u/w/3899-2062318.jpg)
OPK News
![OPKO Health to Report Third Quarter 2023 Financial Results on November 6, 2023 OPKO Health to Report Third Quarter 2023 Financial Results on November 6, 2023](https://cdn.snapi.dev/images/v1/y/m/conf4-2130070.jpg)
By GlobeNewsWire
October 31, 2023
OPKO Health to Report Third Quarter 2023 Financial Results on November 6, 2023
MIAMI, Oct. 31, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and nine months more_horizontal
![OPKO Health to Present New Clinical Data on Rayaldee (ER Calcifediol) at Kidney Week 2023 OPKO Health to Present New Clinical Data on Rayaldee (ER Calcifediol) at Kidney Week 2023](https://cdn.snapi.dev/images/v1/i/a/conf11-2121098.jpg)
By GlobeNewsWire
October 25, 2023
OPKO Health to Present New Clinical Data on Rayaldee (ER Calcifediol) at Kidney Week 2023
MIAMI, Oct. 25, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) will present late-breaking clinical data on RAYALDEE® extended-release calci more_horizontal
![OPKO Health (OPK) Gets BARDA Contract to Combat Antibody Threats OPKO Health (OPK) Gets BARDA Contract to Combat Antibody Threats](https://cdn.snapi.dev/images/v1/f/h/284-2093636.jpg)
By Zacks Investment Research
October 6, 2023
OPKO Health (OPK) Gets BARDA Contract to Combat Antibody Threats
OPKO Health's (OPK) latest awarded funding is likely to enable the development of novel multispecific antibodies against viral infectious disease thre more_horizontal
![OPKO Health (OPK) Ties Up for Oral Peptide Tablet Formulations OPKO Health (OPK) Ties Up for Oral Peptide Tablet Formulations](https://cdn.snapi.dev/images/v1/u/w/3899-2062318.jpg)
By Zacks Investment Research
September 13, 2023
OPKO Health (OPK) Ties Up for Oral Peptide Tablet Formulations
OPKO Health's (OPK) latest Research Collaboration Agreement is likely to enable it to expand its pipeline to develop orally administered tablet presen more_horizontal
![Reasons to Retain OPKO Health (OPK) Stock in Your Portfolio Reasons to Retain OPKO Health (OPK) Stock in Your Portfolio](https://cdn.snapi.dev/images/v1/o/a/1715-2039962.jpg)
By Zacks Investment Research
August 28, 2023
Reasons to Retain OPKO Health (OPK) Stock in Your Portfolio
OPKO Health's (OPK) potential in RAYALDEE raises optimism about the stock. more_horizontal
![OPKO Health (OPK) Q2 Earnings and Revenues Top Estimates OPKO Health (OPK) Q2 Earnings and Revenues Top Estimates](https://cdn.snapi.dev/images/v1/g/p/36484-2010320.jpg)
By Zacks Investment Research
August 7, 2023
OPKO Health (OPK) Q2 Earnings and Revenues Top Estimates
Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall second-quarter results reflect soft perform more_horizontal
![OPKO Health, Inc. (OPK) Q2 2023 Earnings Call Transcript OPKO Health, Inc. (OPK) Q2 2023 Earnings Call Transcript](https://cdn.snapi.dev/images/v1/a/m/transcript37-2006708.jpg)
By Seeking Alpha
August 4, 2023
OPKO Health, Inc. (OPK) Q2 2023 Earnings Call Transcript
OPKO Health, Inc. (NASDAQ:OPK ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Yvonne Briggs - LHA Investor Relations more_horizontal
![OPKO Health (OPK) Reports Q2 Loss, Tops Revenue Estimates OPKO Health (OPK) Reports Q2 Loss, Tops Revenue Estimates](https://cdn.snapi.dev/images/v1/k/9/default20-2006351.jpg)
By Zacks Investment Research
August 3, 2023
OPKO Health (OPK) Reports Q2 Loss, Tops Revenue Estimates
OPKO Health (OPK) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $ more_horizontal